98,054 Shares in Pulse Biosciences, Inc $PLSE Bought by Panoramic Capital LLC

Panoramic Capital LLC acquired a new stake in Pulse Biosciences, Inc (NASDAQ:PLSE) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 98,054 shares of the company’s stock, valued at approximately $2,719,000. Pulse Biosciences comprises 1.2% of Panoramic Capital LLC’s portfolio, making the stock its 24th biggest position. Panoramic Capital LLC owned about 0.14% of Pulse Biosciences at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Russell Investments Group Ltd. grew its holdings in shares of Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after purchasing an additional 619 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the last quarter. Osterweis Capital Management Inc. acquired a new stake in shares of Pulse Biosciences in the 2nd quarter valued at about $28,000. Alliancebernstein L.P. boosted its position in shares of Pulse Biosciences by 6.7% in the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock valued at $365,000 after purchasing an additional 1,300 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after buying an additional 2,156 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Stock Down 1.8%

Shares of NASDAQ PLSE opened at $48.10 on Thursday. The stock has a market capitalization of $3.33 billion, a price-to-earnings ratio of -40.76 and a beta of 1.61. Pulse Biosciences, Inc has a 52 week low of $12.56 and a 52 week high of $50.90. The firm has a 50-day moving average price of $34.48 and a 200 day moving average price of $26.66.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. Equities research analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PLSE. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Mizuho set a $45.00 price target on shares of Pulse Biosciences in a research report on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Needham & Company LLC initiated coverage on shares of Pulse Biosciences in a research report on Monday, August 17th. They set a “buy” rating and a $58.00 price objective on the stock. Finally, Canaccord Genuity Group lifted their price objective on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $45.25.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.